At a glance

ClinicalIndex Comparison Record

Phase 4Completed· 31 enrolled

Drug / intervention

Fesoterodine +1 moredrug

Likely dose

Fesoterodine 4 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01054222

NCT01054222Phase 4Completed

Compare CT.gov

A Local, Multicentre, Open-Label, Extension Trial To Evaluate The Efficacy And Safety Of Fesoterodine Flexible Dose Regimen In Elderly Patients With Overactive Bladder

Pfizer·interventional·Posted Jan 22, 2010·Updated May 15, 2013

In Brief

A Phase 4 clinical trial evaluating Fesoterodine for Urinary Bladder, Overactive. Completed, enrolled 31 participants across 3 sites.

Detailed Summary

This is an open-label extension study intended for subjects who have previously completed study A0221045 (fesoterodine in elderly OAB patients) and who have been recommended by the investigator as being suitable for the extended use of Fesoterodine. Data from this study will extend the evaluation of efficacy, tolerability and safety of Fesoterodine in older subjects from Portugal.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsUrinary Bladder, Overactive

CountriesPortugal

Collaborators--

Timeline

Phase 4CompletedFinished

20102011201220132014201520162017201820192020202120222023202420252026

First PostedJan 2010

Enrollment StartMay 2010

Primary CompletionJan 2012

TodayJul 2026

First PostedJan 22, 2010

Enrollment StartMay 1, 2010

Primary CompletionJan 1, 2012

TodayJul 2, 2026

Enrollment to primary: 1.7 yearsPosted 16.4 years ago

Interventions

Fesoterodinedrug

Fesoterodine fumarate, sustained release (SR) tablet, 4 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)

Fesoterodinedrug

Fesoterodine fumarate, sustained release (SR) tablet, 8 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)